Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
This report elaborates on the current development of the Benign Prostatic Hyperplasia industry thoroughly based on the international market dynamics and China's market situation.
For a start, the report provides an in-depth analysis of the current market situation through three different aspects - by region, by type and by application, which includes market distribution of different types and applications, import and export analysis of major regions, development trends of different types of products in each region, market opportunities and market restrains of different applications.
Secondly, this report lists the major players in the industry, displaying their market positions and strengths and weaknesses of their products, picturing the current competitive situation of the whole market.
Last but not least, the report analyzes and predicts the investment prospects and risks in the industry on the basis of industry data, combined with experts' opinions and suggestions.
By Player:
Sophiris Bio Corp
Pfizer Inc
Boehringer Ingelheim
Astellas Pharma Inc
Nymox Pharmaceutical Corporation
GlaxoSmithKline PLC
Eli Lilly and Company
Allergan PLC
Teva Pharmaceutical Industries Limited
By Type:
Alpha-Blockers
5- Alpha-Reductase Inhibitors (5-Aris)
Alpha-Adrenergic Blockers
Phosphodiesterase-5 Enzyme Inhibitors
Other
By Application:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Research Region:
-
North China
-
Central China
-
South China
-
East China
-
Northeast China
-
Southwest China
-
Northwest China
TABLE OF CONTENT
Chapter 1 China Benign Prostatic Hyperplasia Market Overview 2018-2029
-
1.1 China Benign Prostatic Hyperplasia Industry Development Overview
-
1.2 China Benign Prostatic Hyperplasia Industry Development History
-
1.3 China Benign Prostatic Hyperplasia Industry Market Size (2018-2029)
-
1.4 China Benign Prostatic Hyperplasia Market Analysis by Type from Production Side
-
1.4.1 China Benign Prostatic Hyperplasia Production Volume, Production Value and Growth Rate of Alpha-Blockers (2018-2029)
-
1.4.2 China Benign Prostatic Hyperplasia Production Volume, Production Value and Growth Rate of 5- Alpha-Reductase Inhibitors (5-Aris) (2018-2029)
-
1.4.3 China Benign Prostatic Hyperplasia Production Volume, Production Value and Growth Rate of Alpha-Adrenergic Blockers (2018-2029)
-
1.4.4 China Benign Prostatic Hyperplasia Production Volume, Production Value and Growth Rate of Phosphodiesterase-5 Enzyme Inhibitors (2018-2029)
-
1.4.5 China Benign Prostatic Hyperplasia Production Volume, Production Value and Growth Rate of Other (2018-2029)
-
1.5 China Benign Prostatic Hyperplasia Market Analysis by Application from Consumption End
-
1.5.1 China Benign Prostatic Hyperplasia Sales Volume, Sales Value and Growth Rate of Hospital Pharmacies (2018-2029)
-
1.5.2 China Benign Prostatic Hyperplasia Sales Volume, Sales Value and Growth Rate of Retail Pharmacies (2018-2029)
-
1.5.3 China Benign Prostatic Hyperplasia Sales Volume, Sales Value and Growth Rate of Online Pharmacies (2018-2029)
-
1.6 China Benign Prostatic Hyperplasia Market Analysis by Region
-
1.6.1 North China Benign Prostatic Hyperplasia Market Size and Growth Rate from 2018-2029
-
1.6.2 Central China Benign Prostatic Hyperplasia Market Size and Growth Rate from 2018-2029
-
1.6.3 South China Benign Prostatic Hyperplasia Market Size and Growth Rate from 2018-2029
-
1.6.4 East China Benign Prostatic Hyperplasia Market Size and Growth Rate from 2018-2029
-
1.6.5 Northeast China Benign Prostatic Hyperplasia Market Size and Growth Rate from 2018-2029
-
1.6.6 Southwest China Benign Prostatic Hyperplasia Market Size and Growth Rate from 2018-2029
-
1.6.7 Northwest China Benign Prostatic Hyperplasia Market Size and Growth Rate from 2018-2029
Chapter 2 China Benign Prostatic Hyperplasia Industry Development Environment
-
2.1 Industry Development Environment Analysis
-
2.1.1 Industry Technological Progress Analysis
-
2.1.2 Industrial Organizational Innovation Analysis
-
2.1.3 Changes in Social Habits
-
2.1.4 Alterations in Government Policies
-
2.1.5 Impact of Economic Globalization
-
2.2 Domestic and Foreign Industry Competition Analysis
-
2.2.1 Comparative Analysis on Benign Prostatic Hyperplasia Market Status and Competition at home and abroad in 2023
-
2.2.2 China Benign Prostatic Hyperplasia Market Status and Competition Analysis in 2023
-
2.2.3 China Benign Prostatic Hyperplasia Market Concentration Analysis in 2023
-
2.3 Problems and Countermeasures in the development of China Benign Prostatic Hyperplasia Industry
-
2.3.1 Industry Development Constraints
-
2.3.2 Industry Development Considerations
-
2.3.3 Suggestions on Industry Development Measures
-
2.3.4 Development Strategies for SMEs
-
2.4 Influence of COVID-19 Outbreak on Benign Prostatic Hyperplasia Industry Development
Chapter 3 Benign Prostatic HyperplasiaIndustry Chain Analysis
-
3.1 Benign Prostatic Hyperplasia Industry Chain
-
3.2 Benign Prostatic Hyperplasia Upstream Industry Analysis
-
3.2.1 Upstream Industry Development Status
-
3.2.2 Upstream Industry Development Forecast
-
3.2.3 Impact of Upstream Industry on the Benign Prostatic Hyperplasia Market
-
3.3 Benign Prostatic Hyperplasia Downstream Industry Analysis
-
3.3.1 Downstream Industry Development Status
-
3.3.2 Downstream Industry Development Forecast
-
3.3.3 Impact of Downstream Industry on the Benign Prostatic Hyperplasia Market
Chapter 4 China Benign Prostatic Hyperplasia Market, by Type
-
4.1 China Benign Prostatic Hyperplasia Market Trend, by Type
-
4.2 Product Types of Major Suppliers
-
4.3 Competitive Landscape of Major Types
-
4.4 China Benign Prostatic Hyperplasia Total Production Volume and Growth Rate from Production Side
-
4.5 China Benign Prostatic Hyperplasia Production Volume and Growth Rate, by Type
-
4.5.1 China Benign Prostatic Hyperplasia Production Volume and Growth Rate of Alpha-Blockers
-
4.5.2 China Benign Prostatic Hyperplasia Production Volume and Growth Rate of 5- Alpha-Reductase Inhibitors (5-Aris)
-
4.5.3 China Benign Prostatic Hyperplasia Production Volume and Growth Rate of Alpha-Adrenergic Blockers
-
4.5.4 China Benign Prostatic Hyperplasia Production Volume and Growth Rate of Phosphodiesterase-5 Enzyme Inhibitors
-
4.5.5 China Benign Prostatic Hyperplasia Production Volume and Growth Rate of Other
Chapter 5 China Benign Prostatic Hyperplasia Market, by Application
-
5.1 Downstream Market Overview
-
5.2 Competitive Landscape of Major Applications
-
5.3 Market Potential Analysis, by Application
-
5.4 China Benign Prostatic Hyperplasia Total Market Size and Growth Rate from Consumption End
-
5.5 China Benign Prostatic Hyperplasia Market Size and Growth Rate, by Application
-
5.5.1 China Benign Prostatic Hyperplasia Market Size and Growth Rate of Hospital Pharmacies
-
5.5.2 China Benign Prostatic Hyperplasia Market Size and Growth Rate of Retail Pharmacies
-
5.5.3 China Benign Prostatic Hyperplasia Market Size and Growth Rate of Online Pharmacies
Chapter 6 China Benign Prostatic Hyperplasia Market, by Region
-
6.1 China Benign Prostatic Hyperplasia Production Volume and Production Value, by Region
-
6.2 China Benign Prostatic Hyperplasia Sales Volume and Sales Value, by Region
Chapter 7 North China Benign Prostatic Hyperplasia Market Analysis
-
7.1 North China Benign Prostatic Hyperplasia Market, by Type
-
7.2 North China Benign Prostatic Hyperplasia Market, by Application
Chapter 8 Central China Benign Prostatic Hyperplasia Market Analysis
-
8.1 Central China Benign Prostatic Hyperplasia Market, by Type
-
8.2 Central China Benign Prostatic Hyperplasia Market, by Application
Chapter 9 South China Benign Prostatic Hyperplasia Market Analysis
-
9.1 South China Benign Prostatic Hyperplasia Market, by Type
-
9.2 South China Benign Prostatic Hyperplasia Market, by Application
Chapter 10 East China Benign Prostatic Hyperplasia Market Analysis
-
10.1 East China Benign Prostatic Hyperplasia Market, by Type
-
10.2 East China Benign Prostatic Hyperplasia Market, by Application
Chapter 11 Northeast China Benign Prostatic Hyperplasia Market Analysis
-
11.1 Northeast China Benign Prostatic Hyperplasia Market, by Type
-
11.2 Northeast China Benign Prostatic Hyperplasia Market, by Application
Chapter 12 Southwest China Benign Prostatic Hyperplasia Market Analysis
-
12.1 Southwest China Benign Prostatic Hyperplasia Market, by Type
-
12.2 Southwest China Benign Prostatic Hyperplasia Market, by Application
Chapter 13 Northwest China Benign Prostatic Hyperplasia Market Analysis
-
13.1 Northwest China Benign Prostatic Hyperplasia Market, by Type
-
13.2 Northwest China Benign Prostatic Hyperplasia Market, by Application
Chapter 14 Company Profiles
-
14.1 Sophiris Bio Corp
-
14.1.1 Sophiris Bio Corp Company Profile
-
14.1.2 Sophiris Bio Corp Benign Prostatic Hyperplasia Market Performance
-
14.1.3 Product&Service Introduction
-
14.2 Pfizer Inc
-
14.2.1 Pfizer Inc Company Profile
-
14.2.2 Pfizer Inc Benign Prostatic Hyperplasia Market Performance
-
14.2.3 Product&Service Introduction
-
14.3 Boehringer Ingelheim
-
14.3.1 Boehringer Ingelheim Company Profile
-
14.3.2 Boehringer Ingelheim Benign Prostatic Hyperplasia Market Performance
-
14.3.3 Product&Service Introduction
-
14.4 Astellas Pharma Inc
-
14.4.1 Astellas Pharma Inc Company Profile
-
14.4.2 Astellas Pharma Inc Benign Prostatic Hyperplasia Market Performance
-
14.4.3 Product&Service Introduction
-
14.5 Nymox Pharmaceutical Corporation
-
14.5.1 Nymox Pharmaceutical Corporation Company Profile
-
14.5.2 Nymox Pharmaceutical Corporation Benign Prostatic Hyperplasia Market Performance
-
14.5.3 Product&Service Introduction
-
14.6 GlaxoSmithKline PLC
-
14.6.1 GlaxoSmithKline PLC Company Profile
-
14.6.2 GlaxoSmithKline PLC Benign Prostatic Hyperplasia Market Performance
-
14.6.3 Product&Service Introduction
-
14.7 Eli Lilly and Company
-
14.7.1 Eli Lilly and Company Company Profile
-
14.7.2 Eli Lilly and Company Benign Prostatic Hyperplasia Market Performance
-
14.7.3 Product&Service Introduction
-
14.8 Allergan PLC
-
14.8.1 Allergan PLC Company Profile
-
14.8.2 Allergan PLC Benign Prostatic Hyperplasia Market Performance
-
14.8.3 Product&Service Introduction
-
14.9 Teva Pharmaceutical Industries Limited
-
14.9.1 Teva Pharmaceutical Industries Limited Company Profile
-
14.9.2 Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Market Performance
-
14.9.3 Product&Service Introduction
Chapter 15 Research Conclusions and Investment Suggestions
-
15.1 Benign Prostatic Hyperplasia Industry Research Conclusions
-
15.2 Benign Prostatic Hyperplasia Industry Investment Suggestions
-
15.2.1 Suggestions on Industry Development Strategy
-
15.2.2 Suggestions on Industry Investment Direction
-
15.2.3 Suggestions on Industry Investment Strategy
List of Tables and Figures
-
Figure China Benign Prostatic Hyperplasia Industry Market Size (2018-2029)
-
Figure China Benign Prostatic Hyperplasia Production Volume, Production Value and Growth Rate of Alpha-Blockers (2018-2029)
-
Figure China Benign Prostatic Hyperplasia Production Volume, Production Value and Growth Rate of 5- Alpha-Reductase Inhibitors (5-Aris) (2018-2029)
-
Figure China Benign Prostatic Hyperplasia Production Volume, Production Value and Growth Rate of Alpha-Adrenergic Blockers (2018-2029)
-
Figure China Benign Prostatic Hyperplasia Production Volume, Production Value and Growth Rate of Phosphodiesterase-5 Enzyme Inhibitors (2018-2029)
-
Figure China Benign Prostatic Hyperplasia Production Volume, Production Value and Growth Rate of Other (2018-2029)
-
Figure China Benign Prostatic Hyperplasia Sales Volume, Sales Value and Growth Rate of Hospital Pharmacies (2018-2029)
-
Figure China Benign Prostatic Hyperplasia Sales Volume, Sales Value and Growth Rate of Retail Pharmacies (2018-2029)
-
Figure China Benign Prostatic Hyperplasia Sales Volume, Sales Value and Growth Rate of Online Pharmacies (2018-2029)
-
Figure North China Benign Prostatic Hyperplasia Market Size and Growth Rate from 2018-2029
-
Figure Central China Benign Prostatic Hyperplasia Market Size and Growth Rate from 2018-2029
-
Figure South China Benign Prostatic Hyperplasia Market Size and Growth Rate from 2018-2029
-
Figure East China Benign Prostatic Hyperplasia Market Size and Growth Rate from 2018-2029
-
Figure Northeast China Benign Prostatic Hyperplasia Market Size and Growth Rate from 2018-2029
-
Figure Southwest China Benign Prostatic Hyperplasia Market Size and Growth Rate from 2018-2029
-
Figure Northwest China Benign Prostatic Hyperplasia Market Size and Growth Rate from 2018-2029
-
Figure Benign Prostatic Hyperplasia Industry Chain
-
Table Product Types of Major Suppliers in 2023
-
Figure China Benign Prostatic Hyperplasia Market Share by Type in 2018
-
Figure China Benign Prostatic Hyperplasia Market Share by Type in 2023
-
Figure China Benign Prostatic Hyperplasia Total Production Volume and Growth Rate from Production Side (2018-2023)
-
Figure China Benign Prostatic Hyperplasia Production Volume and Growth Rate of Alpha-Blockers (2018-2023)
-
Figure China Benign Prostatic Hyperplasia Production Volume and Growth Rate of 5- Alpha-Reductase Inhibitors (5-Aris) (2018-2023)
-
Figure China Benign Prostatic Hyperplasia Production Volume and Growth Rate of Alpha-Adrenergic Blockers (2018-2023)
-
Figure China Benign Prostatic Hyperplasia Production Volume and Growth Rate of Phosphodiesterase-5 Enzyme Inhibitors (2018-2023)
-
Figure China Benign Prostatic Hyperplasia Production Volume and Growth Rate of Other (2018-2023)
-
Figure China Benign Prostatic Hyperplasia Market Share by Application in 2018
-
Figure China Benign Prostatic Hyperplasia Market Share by Application in 2023
-
Figure China Benign Prostatic Hyperplasia Total Market Size and Growth Rate from Consumption End
-
Figure China Benign Prostatic Hyperplasia Market Size and Growth Rate of Hospital Pharmacies (2018-2023)
-
Figure China Benign Prostatic Hyperplasia Market Size and Growth Rate of Retail Pharmacies (2018-2023)
-
Figure China Benign Prostatic Hyperplasia Market Size and Growth Rate of Online Pharmacies (2018-2023)
-
Table China Benign Prostatic Hyperplasia Production Volume by Region (2018-2023)
-
Table China Benign Prostatic Hyperplasia Production Volume Share by Region (2018-2023)
-
Figure China Benign Prostatic Hyperplasia Production Volume Share by Region (2018-2023)
-
Table China Benign Prostatic Hyperplasia Production Value by Region (2018-2023)
-
Table China Benign Prostatic Hyperplasia Production Value Share by Region (2018-2023)
-
Figure China Benign Prostatic Hyperplasia Production Value Share by Region (2018-2023)
-
Table China Benign Prostatic Hyperplasia Sales Volume by Region (2018-2023)
-
Table China Benign Prostatic Hyperplasia Sales Volume Share by Region (2018-2023)
-
Figure China Benign Prostatic Hyperplasia Sales Volume Share by Region (2018-2023)
-
Table China Benign Prostatic Hyperplasia Sales Value by Region (2018-2023)
-
Table China Benign Prostatic Hyperplasia Sales Value Share by Region (2018-2023)
-
Figure China Benign Prostatic Hyperplasia Sales Value Share by Region (2018-2023)
-
Table North China Benign Prostatic Hyperplasia Production Volume by Type (2018-2023)
-
Table North China Benign Prostatic Hyperplasia Production Volume Share by Type (2018-2023)
-
Figure North China Benign Prostatic Hyperplasia Production Volume Share by Type (2018-2023)
-
Table North China Benign Prostatic Hyperplasia Sales Volume by Application (2018-2023)
-
Table North China Benign Prostatic Hyperplasia Sales Volume Share by Application (2018-2023)
-
Figure North China Benign Prostatic Hyperplasia Sales Volume Share by Application (2018-2023)
-
Table Central China Benign Prostatic Hyperplasia Production Volume by Type (2018-2023)
-
Table Central China Benign Prostatic Hyperplasia Production Volume Share by Type (2018-2023)
-
Figure Central China Benign Prostatic Hyperplasia Production Volume Share by Type (2018-2023)
-
Table Central China Benign Prostatic Hyperplasia Sales Volume by Application (2018-2023)
-
Table Central China Benign Prostatic Hyperplasia Sales Volume Share by Application (2018-2023)
-
Figure Central China Benign Prostatic Hyperplasia Sales Volume Share by Application (2018-2023)
-
Table South China Benign Prostatic Hyperplasia Production Volume by Type (2018-2023)
-
Table South China Benign Prostatic Hyperplasia Production Volume Share by Type (2018-2023)
-
Figure South China Benign Prostatic Hyperplasia Production Volume Share by Type (2018-2023)
-
Table South China Benign Prostatic Hyperplasia Sales Volume by Application (2018-2023)
-
Table South China Benign Prostatic Hyperplasia Sales Volume Share by Application (2018-2023)
-
Figure South China Benign Prostatic Hyperplasia Sales Volume Share by Application (2018-2023)
-
Table East China Benign Prostatic Hyperplasia Production Volume by Type (2018-2023)
-
Table East China Benign Prostatic Hyperplasia Production Volume Share by Type (2018-2023)
-
Figure East China Benign Prostatic Hyperplasia Production Volume Share by Type (2018-2023)
-
Table East China Benign Prostatic Hyperplasia Sales Volume by Application (2018-2023)
-
Table East China Benign Prostatic Hyperplasia Sales Volume Share by Application (2018-2023)
-
Figure East China Benign Prostatic Hyperplasia Sales Volume Share by Application (2018-2023)
-
Table Northeast China Benign Prostatic Hyperplasia Production Volume by Type (2018-2023)
-
Table Northeast China Benign Prostatic Hyperplasia Production Volume Share by Type (2018-2023)
-
Figure Northeast China Benign Prostatic Hyperplasia Production Volume Share by Type (2018-2023)
-
Table Northeast China Benign Prostatic Hyperplasia Sales Volume by Application (2018-2023)
-
Table Northeast China Benign Prostatic Hyperplasia Sales Volume Share by Application (2018-2023)
-
Figure Northeast China Benign Prostatic Hyperplasia Sales Volume Share by Application (2018-2023)
-
Table Southwest China Benign Prostatic Hyperplasia Production Volume by Type (2018-2023)
-
Table Southwest China Benign Prostatic Hyperplasia Production Volume Share by Type (2018-2023)
-
Figure Southwest China Benign Prostatic Hyperplasia Production Volume Share by Type (2018-2023)
-
Table Southwest China Benign Prostatic Hyperplasia Sales Volume by Application (2018-2023)
-
Table Southwest China Benign Prostatic Hyperplasia Sales Volume Share by Application (2018-2023)
-
Figure Southwest China Benign Prostatic Hyperplasia Sales Volume Share by Application (2018-2023)
-
Table Northwest China Benign Prostatic Hyperplasia Production Volume by Type (2018-2023)
-
Table Northwest China Benign Prostatic Hyperplasia Production Volume Share by Type (2018-2023)
-
Figure Northwest China Benign Prostatic Hyperplasia Production Volume Share by Type (2018-2023)
-
Table Northwest China Benign Prostatic Hyperplasia Sales Volume by Application (2018-2023)
-
Table Northwest China Benign Prostatic Hyperplasia Sales Volume Share by Application (2018-2023)
-
Figure Northwest China Benign Prostatic Hyperplasia Sales Volume Share by Application (2018-2023)
-
Table Sophiris Bio Corp Company Profile
-
Table Sophiris Bio Corp Benign Prostatic Hyperplasia Revenue, Price and Gross (2018-2023)
-
Table Pfizer Inc Company Profile
-
Table Pfizer Inc Benign Prostatic Hyperplasia Revenue, Price and Gross (2018-2023)
-
Table Boehringer Ingelheim Company Profile
-
Table Boehringer Ingelheim Benign Prostatic Hyperplasia Revenue, Price and Gross (2018-2023)
-
Table Astellas Pharma Inc Company Profile
-
Table Astellas Pharma Inc Benign Prostatic Hyperplasia Revenue, Price and Gross (2018-2023)
-
Table Nymox Pharmaceutical Corporation Company Profile
-
Table Nymox Pharmaceutical Corporation Benign Prostatic Hyperplasia Revenue, Price and Gross (2018-2023)
-
Table GlaxoSmithKline PLC Company Profile
-
Table GlaxoSmithKline PLC Benign Prostatic Hyperplasia Revenue, Price and Gross (2018-2023)
-
Table Eli Lilly and Company Company Profile
-
Table Eli Lilly and Company Benign Prostatic Hyperplasia Revenue, Price and Gross (2018-2023)
-
Table Allergan PLC Company Profile
-
Table Allergan PLC Benign Prostatic Hyperplasia Revenue, Price and Gross (2018-2023)
-
Table Teva Pharmaceutical Industries Limited Company Profile
-
Table Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Revenue, Price and Gross (2018-2023)
-
